Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolebrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolebrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2023
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR443820 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2023
Details : SAR443820 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2023
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
Details : SAR443820 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2023
Details : SAR443820 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 29, 2021
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects
Details : SAR442168 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2019
Lead Product(s) : Tolebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DNL747
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Denali Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Details : DNL747 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 28, 2018
Lead Product(s) : DNL747
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Denali Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Valproate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2018
Lead Product(s) : Sodium Valproate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Details : GZ402668 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis, Chronic Progressive.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 30, 2016
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
